IL17D and psoriasis: In contrast to IL-36R, sIL-36R was gradually reduced in whole skin lesions from wild-type mice at day 8 post-MC903 administration or at day 2 post-IMQ-administration (Fig. 5e,f) and was almost undetectable in skin lesions from patients with AD or psoriasis or from MC903- and IMQ-treated Ddx5∆KC mice (Fig. 5g–j), whereas its expression in skin lesions from MC903- and IMQ-treated Il17d–/– and Cd93–/– mice was similar to that in healthy skin from wild-type mice (Fig. 5k–n).